Medical Director, The Progeria Research Foundation (PRF), Peabody, MA; Professor of Pediatrics Research, Warren Alpert Medical School of Brown University and Dept. of Pediatrics, Hasbro Children’s Hospital, Providence, RI; Research Associate, Department of Anesthesia, Boston Children’s Hospital Boston and Harvard Medical School, Boston, MA.

Dr. Gordon, founder of The Progeria Research Foundation, and co-author of the Progeria gene discovery has served as Chair of PRF’s ten previous international scientific workshops.  She serves as Principal Investigator for The PRF International Registry, Diagnostic Testing Program, Cell & Tissue Bank, and Medical & Research Database. Dr. Gordon has co-chaired four clinical treatment trials for children with Progeria, all conducted at Boston Children’s Hospital.

President and Executive Director, The Progeria Research Foundation, Peabody, MA.

Attorney Gordon, co-founder of PRF, is responsible for ensuring PRF’s financial growth, program development, and day-to-day management. She has been the project administrator for all ten PRF international scientific workshops on Progeria.

Senior Investigator, Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, and Director of Department of Basic Research, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Dr. Andrés and his team are investigating the role of A-type lamins in the regulation of pathophysiological processes, including HGPS. Major efforts in his laboratory are directed towards the generation of new animal models of HGPS with the goal of elucidating mechanisms of the disease and testing novel therapies, with special emphasis on cardiovascular alterations. He is a member of PRF’s Medical Research Committee.

Judith Campisi received a PhD from the State University of New York, and postdoctoral training at the Harvard Medical School.  She was on the Boston University Medical School faculty before joining the Lawrence Berkeley National Laboratory in 1991.  In 2002, she started a second laboratory at the Buck Institute for Research on Aging.  At both institutions, she established a broad program to understand the relationship between aging and disease, with an emphasis on aging and cancer.  Her laboratory made several pioneering discoveries in these areas.  She has received numerous awards for her research, is an elected member of the National Academy of Sciences, and serves on numerous editorial and scientific advisory boards.

Dr. Kieran is currently the Pediatric Clinical Trial Lead in Oncology Clinical Development, Bristol-Myers Squibb. His laboratory and clinical programs have focused on the genomic identification of mutations and incorporation of targeted, biologic, immune and gene therapy for children with brain tumors and other genetic diseases. He was the principle investigator of the first three clinical trials for children with Progeria using the targeted agent lonafarnib.